Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells

The overall five-year survival rate for late-stage patients of ovarian cancer is below 29% due to disease recurrence and drug resistance. Cancer stem cells (CSCs) are known as a major contributor to drug resistance and recurrence. Accordingly, therapies targeting ovarian CSCs are needed to overcome...

Descripció completa

Dades bibliogràfiques

Autors principals:	Heejin Lee, Oh-Bin Kwon, Jae-Eon Lee, Yong-Hyun Jeon, Dong-Seok Lee, Sang-Hyun Min, Jun-Woo Kim
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2021-04-01
Col·lecció:	Cells
Matèries:	trimebutine maleate ovarian cancer stem cells BKCa channel Ca<sup>2+</sup> channel wnt/β-catenin signaling
Accés en línia:	https://www.mdpi.com/2073-4409/10/4/918
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!